Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results
10 nov. 2021 05h55 HE
|
Novan, Inc.
– Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum – –...
Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treatment of COVID-19
09 nov. 2021 08h35 HE
|
Novan, Inc.
– Data indicate that intranasal administration of SB019 formulation containing berdazimer sodium is well-tolerated and safe under the conditions of preclinical study – – Company believes the...
Novan Announces Fireside Chat Hosted by Jonathan Aschoff, Ph.D. of ROTH Capital Partners
04 nov. 2021 09h00 HE
|
Novan, Inc.
– Company highlights rationale of strategic pathway towards potential commercialization in collaboration with commercial solutions provider, Syneos Health – – Discusses recent progress and expected...
Novan to Report Third Quarter 2021 Financial Results on November 10, 2021
03 nov. 2021 09h00 HE
|
Novan, Inc.
DURHAM, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2021 financial results on Wednesday,...
Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand Name KINSOLUS™ for SB206 in Molluscum Contagiosum
02 nov. 2021 08h30 HE
|
Novan, Inc.
– Mr. Johnson brings broad commercial expertise with over 30 years of leadership spanning dermatology marketing, sales, sales management, digital marketing and managed care –– Company received...
Veterinary Telemedicine Market to Surpass US$ 95.2 Million by 2028, Says Coherent Market Insights (CMI)
27 oct. 2021 09h10 HE
|
CMI
SEATTLE, Oct. 27, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global veterinary telemedicine market is estimated to be valued at US$ 31.2 million in 2021 and is expected to...
Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206
23 sept. 2021 08h00 HE
|
Novan, Inc.
– SB206 demonstrates continued favorable safety profile consistent with previous studies and meets Company’s expectations – – Pre-NDA meeting with the FDA, as well as conduct of customary stability...
Novan to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
20 sept. 2021 09h00 HE
|
Novan, Inc.
DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan,...
Novan Announces Strategic Priorities and Outlines Key Milestones
09 sept. 2021 07h00 HE
|
Novan, Inc.
– Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum – – Late-stage...
Novan Engages Syneos Health as Commercial Solutions Provider for SB206
08 sept. 2021 09h00 HE
|
Novan, Inc.
– Company targeting New Drug Application (NDA) for SB206 in Q3 2022, following recent clinically and statistically significant topline efficacy results from a pivotal Phase 3 B-SIMPLE4 trial in...